Clinical Trial Update: Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating HIV-1 gp120 protein vaccine in HIV-uninfected adults with quiescent systemic lupus erythematosus has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections
• Systemic Lupus Erythematosus

Drugs mentioned

• HIV-1 gp120 protein vaccine (gp120 protein vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections, Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED | Results posted: 2021-12-29